Physician profile
Dana E Wilkinson
NPI 1386747426
$3,154.79
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.45 · 2022: $433 · 2023: $1,421 · 2024: $1,290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,710.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,710.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $534.63 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $412.41 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $402.88 | 2022-2024 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $285.14 | 2022-2024 | |
| Abbvie INC. | $270.68 | 2022-2024 | |
| Mylan Specialty L.P. | $183.44 | 2023-2024 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $177.47 | 2023-2024 | Rexulti, Nuedexta |
| Pfizer INC. | $159.59 | 2023-2024 | |
| Glaxosmithkline, LLC. | $120.14 | 2023-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $103.21 | 2022-2024 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals Lp | $93.10 | 2023-2024 | Airsupra, Breztri, Farxiga |
| Esperion Therapeutics, INC. | $55.59 | 2023-2024 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.36 | 2023-2024 | Synjardy, Jardiance |
| Sanofi Pasteur INC. | $44.47 | 2023-2024 | |
| Shield Therapeutics INC | $39.02 | 2022-2023 | Accrufer |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $37.18 | 2023 | Quviviq |
| Organogenesis INC. | $32.19 | 2024 | Puraply Am |
| Biohaven Pharmaceutical Holding Company Ltd. | $22.29 | 2022 | |
| Dexcom, INC. | $21.67 | 2023 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $20.55 | 2024 | Voquezna |
| Ironwood Pharmaceuticals, INC | $19.14 | 2023 | Linzess |
| Exact Sciences Corporation | $16.16 | 2023 | Cologuard Collection Kit |
| Corium, LLC | $15.60 | 2023 | Adlarity |
| Impel Pharmaceuticals INC. | $15.50 | 2023 | Trudhesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.61 | 2024 | Xifaxan, Trulance |
| Avion Pharmaceuticals | $12.77 | 2023 | Methylphenidate Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Wilkinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.